PMID- 19626462
OWN - NLM
STAT- MEDLINE
DCOM- 20100929
LR  - 20211020
IS  - 1573-2649 (Electronic)
IS  - 0962-9343 (Linking)
VI  - 18
IP  - 8
DP  - 2009 Oct
TI  - Health utility scores of colorectal cancer based on societal preference in Japan.
PG  - 1095-103
LID - 10.1007/s11136-009-9513-z [doi]
AB  - PURPOSE: We measured health utility scores of colorectal cancer (CRC) patients 
      from a societal perspective in Japan. METHODS: Twenty-five states of health were 
      described: four metastatic states without severe adverse events (AEs), 16 
      metastatic states with Grade 3/4 AEs, four adjuvant states, and one terminal 
      state. A total of 1,500 respondents stratified by age and gender were recruited 
      randomly from the largest Web-panel in Japan. Respondents were allocated randomly 
      to three of the 25 health states and answered questionnaires by standard gamble 
      (SG) and time trade-off (TTO) methods. RESULTS: Although utility scores of 
      metastatic CRC receiving XELOX (capecitabine plus oxaliplatin) chemotherapy were 
      0.48(SG and TTO) (with stoma) and 0.57(SG) or 0.59(TTO) (without stoma), utility 
      scores of those receiving FOLFOX4 (5-fluorouracil/folinic acid and oxaliplatin) 
      chemotherapy were 0.42(SG) or 0.43(TTO) (with stoma) and 0.52(SG) or 0.53(TTO) 
      (without stoma). These differences between XELOX and FOLFOX4 were statistically 
      significant (P = 0.0198 in SG and P = 0.0059 in TTO). Stage 3/4 AEs decreased 
      utility scores to 0.35-0.4 and 0.4-0.45 in the presence and absence of stoma, 
      respectively. CONCLUSIONS: XELOX was generally considered a significantly 
      preferable chemotherapy regimen compared to FOLFOX4 for CRC in Japan. Almost all 
      Grade 3/4 AEs and stoma significantly decreased utility scores. These differences 
      are dependent on the accuracy of the health state description and to confirm 
      these results. In future research, it would be preferable that preference-based 
      HRQoL measures are used directly in patients if utility scores are practically 
      measurable by such method.
FAU - Shiroiwa, Takeru
AU  - Shiroiwa T
AD  - Department of Drug Policy and Management, Graduate School of Pharmaceutical 
      Sciences, The University of Tokyo, Tokyo, Japan. t.shiroiwa@gmail.com
FAU - Fukuda, Takashi
AU  - Fukuda T
FAU - Tsutani, Kiichiro
AU  - Tsutani K
LA  - eng
PT  - Journal Article
DEP - 20090721
PL  - Netherlands
TA  - Qual Life Res
JT  - Quality of life research : an international journal of quality of life aspects of 
      treatment, care and rehabilitation
JID - 9210257
RN  - 0 (Organoplatinum Compounds)
RN  - 0 (Oxaloacetates)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
RN  - Folfox protocol
RN  - XELOX
SB  - IM
MH  - Adaptation, Psychological
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Capecitabine
MH  - Colorectal Neoplasms/*drug therapy/mortality
MH  - Deoxycytidine/analogs & derivatives/therapeutic use
MH  - Female
MH  - Fluorouracil/analogs & derivatives/therapeutic use
MH  - Health Knowledge, Attitudes, Practice
MH  - Health Status Indicators
MH  - Health Surveys
MH  - Humans
MH  - Japan/epidemiology
MH  - Leucovorin/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Organoplatinum Compounds/therapeutic use
MH  - Oxaloacetates
MH  - *Patient Satisfaction
MH  - *Quality of Life
MH  - Sex Factors
MH  - *Social Perception
MH  - Statistics as Topic
MH  - *Stress, Psychological
MH  - Surveys and Questionnaires
EDAT- 2009/07/25 09:00
MHDA- 2010/09/30 06:00
CRDT- 2009/07/24 09:00
PHST- 2008/10/14 00:00 [received]
PHST- 2009/07/06 00:00 [accepted]
PHST- 2009/07/24 09:00 [entrez]
PHST- 2009/07/25 09:00 [pubmed]
PHST- 2010/09/30 06:00 [medline]
AID - 10.1007/s11136-009-9513-z [doi]
PST - ppublish
SO  - Qual Life Res. 2009 Oct;18(8):1095-103. doi: 10.1007/s11136-009-9513-z. Epub 2009 
      Jul 21.